formoline L112
Commercial- Indications
- Overweight, Obesity
Company intelligence / Profile preview
Certmedica International GmbH
Aschaffenburg, Bavaria/Bayern, Germanycertmedica.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Certmedica has completed multiple clinical trials demonstrating efficacy of its polyglucosamine-based medical device (formoline L112) for reducing cholesterol absorption and supporting weight management. Additional studies include artificial saliva spray for xerostomia in diabetes type II patients.[3]
- Therapeutic areas
- EndocrinologyCardiovascularMetabolic Disorders
- Modalities
- Medical devicesNutritional supplementsCosmetics
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Certmedica International GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Certmedica International GmbH.